Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 138.22B |
| Revenue (ttm) | 31.57B |
| Net Income (ttm) | 5.49B |
| Shares Out | n/a |
| EPS (ttm) | 10.12 |
| PE Ratio | 25.18 |
| Forward PE | 14.33 |
| Dividend | 8.59 (3.36%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 495 |
| Average Volume | 313 |
| Open | 258.70 |
| Previous Close | 262.60 |
| Day's Range | 255.30 - 261.75 |
| 52-Week Range | 230.75 - 318.05 |
| Beta | 0.48 |
| RSI | 49.08 |
| Earnings Date | Aug 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca Plc (NASDAQ: AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gM...
Dow Leads as Health Care Stocks Merck and Amgen Gain: Stock Market Today
Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.
This Is What Whales Are Betting On Amgen
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ: AMGN). And retail traders should know. We noticed this today when the trades showed up on publicly available optio...
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical a...
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
US stocks close mixed, but near the lows for the day
The major U.S. stock indices closed mixed on the day. The Dow Jones Industrial Average and S&P 500 both ended lower, while the Nasdaq Composite rose, supported by gains in chip stocks. The Russell 200...
Amgen: Great Starting Yield For This Wealth Compounder
What Does the Market Think About Amgen?
Amgen's (NYSE: AMGN) short percent of float has risen 11.34% since its last report. The company recently reported that it has 14.75 million shares sold short , which is 2.75% of all regular shares th...
This House of Representative Just Bought Up To $30K In Amgen Stock
A report on July 9, 2025 shows that Representative Cliff Bentz from Oregon purchase stock in Amgen (NASDAQ: AMGN), valued between $2,002 and $30,000. According to the July filing, the transaction occ...
Amgen: How To Find And Own America's Greatest Opportunities
From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.
Amgen: A Defensive Biotech With Yield And Optionality
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
The Investment Committee give you their top stocks to watch for the second half.
Why Amgen Stock Popped by 4% Today
Flow of funds moves into Dow and small cap stocks.
The market rotated out of the large-cap tech stocks today. Markets got a little spooked by better than expected JOLT job openings and the realization that July is probably not a month for a rate cut. ...
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
Argenx SE (NASDAQ: ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgar...
Amgen, Zai Lab succeed in gastric cancer study
Amgen's gastric cancer drug meets late-stage trial goal
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif. , June 30, 202...
Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus
Before this week Amgen hasn't been able to generate excitement for its GLP-1, says Jim Cramer
'Mad Money' host Jim Cramer looks into stock movement connected to Amgen's GLP-1 offerings.
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen Inc (NASDAQ: AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcu...
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a...